Skip to main content

Table 1 Clinical characteristics of n = 19 consecutive patients treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma.

From: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

median age (range) at time of HFSRT 50 years (11–74 years)
male / female 8 (42%)/11(58%)  
median Karnofsky performance score at time of HFSRT (range) 90 (60–90)
initial histology   
astrocytoma II° 3 (16%)  
pure anaplastic astrocytoma III° 4 (21%)  
anaplastic oligoastrocytoma or oligodendroglioma III° 3 (16%)  
glioblastoma multiforme IV° 9 (47%)  
most recent histology before HFSRT   
anaplastic astrocytoma III° 5 (26%)  
glioblastoma multiforme IV° 14 (74%)  
initial surgical procedure   
resection 15 (79%)  
biopsy 4 (21%)  
post-operative radiotherapy   
1.8–2.0 Gy daily (total dose 54 to 61 Gy) 12 (63%)  
3 Gy daily (total dose 45 Gy) 2 (11%)  
2 × 1.8 Gy daily (total dose 54 Gy) 5 (26%)  
salvage surgery before HFSRT 12 (63%)  
adjuvant or salvage chemotherapy before HFSRT   
nimustine / teniposide 12 (63%)  
temozolomide 5 (26%)  
other 1 (5%)  
median interval post-OP radiotherapy to HFSRT (range) 19 months (3–116 months)